Navigation Links
Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection
Date:9/8/2011

PINE BROOK, N.J., Sept. 8, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a  biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection (IM). The five year contract, totaling up to $68.9 million, will support multiple animal efficacy studies as well as human safety studies to further demonstrate the utility of Anthim (ETI-204), the company's anti-toxin, to prevent disease and death from exposure to anthrax when administered intramuscularly before symptoms of disease are present.  Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack. Intramuscular injection allows for the rapid administration of a single-dose of anti-toxin to large numbers of people outside of a hospital or medical setting and will not require trained medical personnel, intravenous bags, sterile mixing and other preparations needed for intravenous administration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO)

"Many more people can quickly receive prophylactic treatment against anthrax infection using intramuscular administration, particularly in an emergency setting before symptoms are present," said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. "In several  animal studies conducted to date, ETI-204 has demonstrated excellent efficacy and increased survival significantly when given in a single intramuscular dose. We are pleased to continue the advanced development of Anthim for prophylactic therapy against anthrax toxemia."  

Anthrax is a life-threatening infectious disease caused by the bacteria Bacillus anthracis and remains one of the nation's top biowarfare threats. Inhaled anthrax is often fatal, even if treated with antibiotics, if not treated soon after exposure. If all activities in the ETI-204 development program are completed to the U.S. Food and Drug Administration's (FDA) satisfaction, the federal government could purchase Anthim for the Strategic National Stockpile (SNS) under Project BioShield. Project BioShield was established in 2004 to provide much needed funding to procure important countermeasures to protect the American public in the event of a biowarfare attack.

This funding is in addition to a separate contract, totaling up to $143 million over five years, previously awarded for development of Anthim for treatment of symptomatic patients. Funding will be provided by the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. 

Leslie Casey, PhD, Vice President of Research commented that, "In a recent animal study, a single IM dose of Anthim provided a 92% survival rate when administered 18 hours after exposure to anthrax. All surviving animals tested negative for anthrax bacteria by study day 14. The results of this study, in addition to other animal studies previously conducted by the company, continue to demonstrate the significant survival benefit of ETI-204 when given to anthrax exposed animals." This research was funded by the U.S. Department of Defense, Joint Program Executive Office for Chemical and Biological Defense - Chemical Biological Medical Systems/DoD, contract number W9113M-10-C-0024.

Elusys has completed two safety studies in humans with Anthim and numerous studies demonstrating safety and efficacy in animal models. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA.

About Anthim

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack.

Anthim has been extensively tested for efficacy and safety in animals and safety in human volunteers. It shows excellent potential as an effective, life-saving therapeutic for the treatment of people infected by or exposed to anthrax spores. A single dose of Anthim consistently protects 70% to 100% of anthrax-infected animals from death.

This project is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201000026C, the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), and the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C.

About Elusys Therapeutics, Inc.

Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Elusys has been engaged in development of biodefense countermeasures since 2000. The company has established experience in government contract management and to date has received multiple grants and contracts totally up to $246 million in government funding. Anthim, a highly effective, anthrax anti-toxin, is in late-stage development, and is a strong candidate for future procurement into the Strategic National Stockpile. For more information, please visit www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
2. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
3. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
4. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
5. Sanmina-SCI Kenosha, Wisconsin Facility Awarded ISO 13485 Certification for Medical Devices
6. Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application
7. USANA Awarded the NutriSearch Gold Medal of Achievement™
8. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
9. Inogen Awarded Department of Veterans Affairs Contract
10. Meaningful Use Certification Awarded to Press Ganeys Quality Performer(SM)
11. PCB Leader Mass Design Awarded Medical Device Manufacturing Certification ISO 13485:2003
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
Breaking Medicine Technology:
(Date:5/31/2016)... Prairie, MN (PRWEB) , ... May 31, 2016 , ... ... from the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO ... most common means of achieving a leak-free connection between two medical devices (e.g. a ...
(Date:5/31/2016)... Greifensee, Switzerland (PRWEB) , ... May 31, 2016 , ... ... adopt this model in their laboratories as well. However, laboratories have different challenges compared ... many benefits of lean operations in the lab, METTLER TOLEDO has developed the ...
(Date:5/31/2016)... ... , ... In his latest video, renowned AstroNumerologist Jesse Kalsi ... presidential candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys ... adding numbers up,” says Kalsi. “It is about looking at each individual number, ...
(Date:5/31/2016)... ... May 31, 2016 , ... Phynd Technologies, Inc. announced recently the ... – Houston, TX and Shore Medical Center – Somers Point, NJ. The new clients ... EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. , Houston Methodist ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta attained his Doctor of ... the class of 1986, where he graduated in the top ten percentile of his ... Livingston since 1989. He has been a member in good standing for thirty years ...
Breaking Medicine News(10 mins):